On July 16th, 2017, Hexaell Biotechnology Co., Ltd., the first portfolio company of iCCAMT opened its new R&D center for cell engineering and human bio-artificial liver program in iCCAMT building in Jiading Industrial Park of Shanghai. The opening ceremony was combined with a mini- symposium of “Severe Liver Disease and Biotechnology Symposium” co-organized with China Cell Biology Association.

Hexaell Biotechnology Co., Ltd is a start-up company pioneering in stem cell and artificial organ. The disruptive technologies were original published in "Nature. 475(7356):386-9" and "Cell Stem Cell. 14(3):370-84" from Chinese Academy of Sciences. Hexaell Biotechnology had licensed iHep and HiHep technologies from Chinese Academy of Sciences and developed medical devices of bio-artificial liver to replace liver function of human and cure liver failure diseases. Hexaell has finished pilot clinical studies in 6 liver failure patients in leading hepatopathy centers in China.

Prof. Pei Gang, former president of Tongji University

Mr. Huadi Shen, vice mayor of Jiading District, was giving a speech

Dr. Guoyu Pan, Chair of Hexaell, was presenting the bio-artificial liver projects. 

Prof. Robert Fisher, director of Organ Transplant Institute of Harvard Medical School was explaining the technology of liver cell transplantation.

Mr. Jianhua Yu, Party Secretary of Jiading industrial zone, and Dr. Guoyu Pan unveiled the logo of Hexaell

Hexaell Biotechnology team at the event

Dr. Liqun Wang, CEO of Fosun Kite and Dr. Hui Wu, co-founder of Hexaell and founder of iCCAMT in lunch break.

Group photograph of the event

The iCCAMT team was deeply involved in the founding of the Hexaell Biotechnology and provided services to technology transfer, business development, investor relationship, governmental affairs and international cooperations, thus laid a solid foundation for the landing of the project.